About KBP BioSciences
KBP BioSciences is a Healthcare company based in Princeton (United States) founded in 2007. Therapeutics for kidney disease, infections, and respiratory conditions are developed. KBP BioSciences has raised $76 million across 1 funding round from investors including SDIC, Efung Capital and Advantech Capital. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Heart Failure. Its competitors include AskBio, Insmed and Affinivax; 2 of its 3 listed competitors have raised funding.
Company details
KBP Biosciences is developing medicine with a focus on following therapeutic areas: inflammatory and autoimmune diseases, major organ degeneration, and drug-resistant bacterial infection, as well as cancers and gastrointestinal disorders. Its drug pipeline inlcudes KBP-5074 (MR-specific antogonist) Chronic Kidney DiseaseHeart Failure (Phase 2); KBP-7072, a next generation tetracycline for multi-resistant bacterial infection (Phase 1). The company also have drug sin development for Asthma COPD; Fibrosis; Rheumatoid arthritis and Gram-Negative bacteria infections.
- Headquarters Princeton, United States
- SectorsHealthcare
- Email••••••••
- Website kbpbio.com
- Social LinkedIn
- Total Equity Funding$76M (USD)
in 1 rounds
- Latest Funding Round$76M (USD), Series A
Jan 2018
- InvestorsSDIC
& 9 more
Funding Insights of KBP BioSciences
KBP BioSciences has successfully raised a total of $76M through 1 strategic funding round. The most recent funding activity was a Series A round of $76 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $76M
- Total Rounds 1
- Last Round Series A — $76M
- First Round $76M
(Jan 2018)
- Investors Count 10
All 1 funding rounds of KBP BioSciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2018 | $76M | Series A | – | Advantech Capital, SDIC |
10 investors in total: 10 institutional.
Investors in KBP BioSciences
KBP BioSciences has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include SDIC, Efung Capital and Advantech Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Efung Capital is focused on global biopharmaceutical investments. | 2012 | efungcapital.com | Shenzhen, China | |
| advantechcapital.com | ||||
A venture capital firm focused on life sciences investments. | sangelvc.com | Shenzhen, China | ||
Corporate-backed venture capital firm focused on retail tech, mobile tech, and multiple sectors | pinganventures.com | Pudong, China | ||
| cowincapital.com.cn | ||||
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
| elite-capital.com | ||||
Tech startups are invested in by this venture capital firm. | kipvc.cn | Singapore, Singapore | ||
Investment holding company | 1995 | sdic.com.cn | Beijing, China | |
Investment management services are provided by Guangfa Xinde. | gfxdtz.icoc.in | China |
Investor details for KBP BioSciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of KBP BioSciences
2 dated milestones of KBP BioSciences across 11 years, from founding to its latest funding, stage changes and deals.
- Founded KBP BioSciences is founded.
- Funding First funding round of $76.0M.
Competitors of KBP BioSciences
KBP BioSciences has 3 listed competitors in our database, 2 of them funded. They include AskBio, Insmed and Affinivax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. | ||
| insmed.com | 1999 | Bridgewater, United States | 912 | Developer of small molecule inhibitors for rare lung diseases | ||
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. |
Detailed competitors of KBP BioSciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as KBP BioSciences (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kbp Biosciences
Complete news archive for KBP BioSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about KBP BioSciences
KBP BioSciences was founded in 2007 and raised its 1st funding round 11 years after it was founded.
KBP BioSciences is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
KBP BioSciences is a funded company, having raised a total of $76M across 1 funding round to date. The company's 1st funding round was a Series A of $76M, raised on Jan 2018.
KBP Biosciences is developing medicine with a focus on following therapeutic areas: inflammatory and autoimmune diseases, major organ degeneration, and drug-resistant bacterial infection, as well as cancers and gastrointestinal disorders. Its drug pipeline inlcudes KBP-5074 (MR-specific antogonist) Chronic Kidney DiseaseHeart Failure (Phase 2); KBP-7072, a next generation tetracycline for multi-resistant bacterial infection (Phase 1). The company also have drug sin development for Asthma COPD; Fibrosis; Rheumatoid arthritis and Gram-Negative bacteria infections.
KBP BioSciences has 10 investors. Key investors include SDIC, Efung Capital, Advantech Capital, Sangel Capital, and Ping An Ventures.